COVID-19 as a viral infection is usually asymptomatic in children, but complications of this disease are not rare in children. Hyper inflammation of COVID-19 is a potentially fatal in undiagnosed children. It is very similar to Kawasaki disease, but with higher mortality and morbidity. Multi-organ involvement was reported in hyper inflammation syndrome following COVID-19.

In this Research Topic, we will explore the management of hyper inflammation syndrome in children due to COVID- 19, and the obstacles pediatric physicians currently face. We welcome full research articles including original findings, review articles, systemic reviews, meta-analysis, and case reports, covering but not limited to, the following themes:

· Heterogeneity of manifestations of hyper inflammation syndrome in children

· Cardiac involvement in hyper inflammation syndrome in children

· Gastrointestinal and hepatobilary involvement in hyper inflammation syndrome in children

· Kidney and urinary tract involvement in hyper inflammation syndrome in children

· Respiratory system involvement in hyper inflammation syndrome in children

· Central and peripheral nervous system involvement in hyper inflammation syndrome

· Musculoskeletal manifestation of hyper inflammation syndrome in children

· Hematologic manifestation of hyper inflammation syndrome in children

· Dermatologic manifestation of hyper inflammation syndrome in children

· Management of hyper inflammation syndrome in children under treatment with immunosuppressive treatment

· The role of corticosteroid in management of hyper inflammation syndrome in children

· The role of IVIg in management of hyper inflammation syndrome in children

· The role of biologic drugs in management of hyper inflammation syndrome in children

· Management of hyper inflammation syndrome in children with underlying disease such as rheumatologic disorders, malignancies, chronic respiratory disorders and primary immunodeficiency.

Submit your idea

Impact

Frontiers in Pediatrics

Impact